ArticleBMC infectious diseases2026
Dynamic changes in vasoactive-inotropic score and their prognostic value in severe sepsis and septic shock patients undergoing polymyxin B hemoperfusion: a real-world Asian ICU cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe sepsis and septic shock frequently require escalating vasoactive support, but the prognostic utility of vasoactive-inotropic score (VIS) trajectories during polymyxin B hemoperfusion (PMX-HP) in Asian ICUs remains unclear. We conducted a retrospective single-center cohort study in a tertiary medical ICU in Taiwan, enrolling consecutive adults with severe sepsis or septic shock who received PMX-HP between July 2013 and December 2019. VIS was calculated before PMX-HP (VIS1), immediately after PMX-HP (VIS2), and approximately 24 h post-treatment (VIS3); the primary outcome was 28-day all-cause mortality. In 64 patients, median VIS decreased from 28.8 (IQR 13.0-47.6) at VIS1 to 18.1 (IQR 7.8-45.0) at VIS2 and was 16.9 (IQR 1.3-45.1) at VIS3 among patients with available VIS3 data. VIS1, VIS2, and VIS3 were higher in non-survivors than survivors. A mixed-effects model using log(VIS + 1) confirmed significant effects of time, survival status, and their interaction. In an exploratory time-dependent Cox model, higher time-updated log(VIS + 1) was associated with 28-day mortality. The immediate VIS change showed limited discrimination for 28-day mortality (AUC 0.57, 95% CI 0.43-0.72), whereas VIS3 demonstrated better discrimination (AUC 0.78, 95% CI 0.66-0.91). Adding VIS3 to APACHE II improved discrimination compared with APACHE II alone (AUC 0.81 vs. 0.63; Delta AUC + 0.18; p = 0.020). Kaplan-Meier analysis using the ROC-derived VIS3 cut-off of 14.56 showed significantly worse 28-day survival when VIS3 remained above this threshold. Late post-treatment VIS monitoring may support bedside risk stratification in severe sepsis and septic shock undergoing PMX-HP; multicenter validation is warranted.Clinical trial number Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.